Glenmark has recently launched Remogliflozin - a novel SGLT2 inhibitor- and India is the first country to get access to this innovative drug . Remogliflozin has been studied in 26 clinical trials globally , covering about 2,500 patients from various ethnicities. Phase III clinical trials are the best way to find a new paradigm for treatment and change the way how doctors treat patients. Glenmark invites you for an interactive webinar on 2 nd June 2019 from 11:00 am onwards .
In this webinar , Dr. Anoop Misra and Dr. Bhupen Desai will discuss the "Indian Experience Of Remogliflozin- Phase III Clinical Study" . We invite you to submit your questions which will be answered by the speakers at the end of the session.
